GMP IPO Watch
Nippon India CRISIL-IBX FAR Gilt ETF
Growth · Nippon India Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +1.35% | +3.62% | 199 of 229 |
| YTD | +1.16% | -3.05% | 59 of 229 |
| INCEPTION | +23.36% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Other ETF.
NAV History
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Motilal Oswal Nasdaq Q50 ETF | +33.42% | +31.36% | — | +12.73% |
| Tata Silver Exchange Traded Fund | +26.44% | — | — | +39.36% |
|
SBI Silver ETF
Regular Plan · Growth
|
+26.42% | — | — | +34.10% |
| Kotak Silver ETF | +26.35% | +36.48% | — | +28.03% |
| ICICI PRUDENTIAL SILVER ETF | +26.35% | +36.57% | — | +24.10% |
| Edelweiss Silver ETF | +26.32% | — | — | +35.41% |
| Motilal Oswal Silver ETF | +26.09% | — | — | +46.27% |
|
Nippon India Silver ETF
Direct Plan
|
+26.05% | +36.23% | — | +25.08% |
|
HDFC Silver ETF
Growth Option
|
+25.77% | +36.06% | — | +34.08% |
|
Nippon India Nifty Pharma ETF
Direct Plan
|
+22.83% | +22.93% | +15.06% | +13.35% |
More From Nippon Life India Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Direct Plan · Growth Option
|
+61.78% | +49.40% | — | +24.96% |
|
Nippon India Silver ETF
Direct Plan
|
+26.05% | +36.23% | — | +25.08% |
|
Nippon India Silver ETF FOF
Direct Plan · IDCW Option
|
+24.99% | +35.38% | — | +24.09% |
|
Nippon India Nifty Pharma ETF
Direct Plan
|
+22.83% | +22.93% | +15.06% | +13.35% |
|
Nippon India Japan Equity Fund
Direct Plan · IDCW Option
|
+20.27% | +21.27% | +9.63% | +9.56% |
|
Nippon India ETF Gold BeES
Direct Plan
|
+16.58% | +30.82% | +23.10% | +15.30% |
|
Nippon India Gold Savings Fund
Direct Plan · Growth Option
|
+16.51% | +30.76% | +22.97% | +10.34% |
|
Nippon India US Equity Opportunities Fund
Direct Plan · IDCW Option
|
+11.90% | +18.73% | +10.93% | +14.93% |
|
Nippon India Pharma Fund
Direct Plan · Growth Option
|
+10.54% | +18.85% | +14.53% | +17.34% |
|
Nippon India Fixed Maturity Plan - XLV - Series 5
Direct Plan · Growth Option
|
+7.36% | +8.43% | — | +8.54% |
About This Scheme
Investment Objective
The investment objective of the scheme is to provide investment returns that are commensurate with the total returns of the securities as represented by the CRISIL-IBX FAR Gilt Index before expenses, subject to tracking errors. There is no assurance that the investment objective of the Scheme will be achieved.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.